SG11201810725WA - Novel β-lactamase inhibitors - Google Patents

Novel β-lactamase inhibitors

Info

Publication number
SG11201810725WA
SG11201810725WA SG11201810725WA SG11201810725WA SG11201810725WA SG 11201810725W A SG11201810725W A SG 11201810725WA SG 11201810725W A SG11201810725W A SG 11201810725WA SG 11201810725W A SG11201810725W A SG 11201810725WA SG 11201810725W A SG11201810725W A SG 11201810725WA
Authority
SG
Singapore
Prior art keywords
lactamase inhibitors
novel
disclosed
lactamase
novelb
Prior art date
Application number
SG11201810725WA
Other languages
English (en)
Inventor
Boyu Hu
Charles Z Ding
Zhigang Huang
Ruibin Lin
Minliang Xiao
Jinsheng Xie
Shuhui Chen
Cheng Li
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of SG11201810725WA publication Critical patent/SG11201810725WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201810725WA 2016-06-03 2017-06-02 Novel β-lactamase inhibitors SG11201810725WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610394846 2016-06-03
PCT/CN2017/086999 WO2017206947A1 (zh) 2016-06-03 2017-06-02 新型β-内酰胺酶抑制剂

Publications (1)

Publication Number Publication Date
SG11201810725WA true SG11201810725WA (en) 2018-12-28

Family

ID=60477996

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810725WA SG11201810725WA (en) 2016-06-03 2017-06-02 Novel β-lactamase inhibitors

Country Status (13)

Country Link
US (1) US10738051B2 (ja)
EP (1) EP3466950B1 (ja)
JP (1) JP6929881B2 (ja)
KR (1) KR102392350B1 (ja)
CN (1) CN109311881B (ja)
AU (1) AU2017274131B2 (ja)
CA (1) CA3026322C (ja)
ES (1) ES2863725T3 (ja)
MY (1) MY193239A (ja)
RU (1) RU2741963C2 (ja)
SG (1) SG11201810725WA (ja)
WO (1) WO2017206947A1 (ja)
ZA (1) ZA201808552B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3719020B1 (en) * 2017-12-01 2022-09-21 Qilu Pharmaceutical Co., Ltd. Crystal form of beta-lactamase inhibitor and preparation method therefor
EP3747883A4 (en) * 2018-01-29 2020-12-16 Medshine Discovery Inc. B-LACTAM MONOCYCLIC COMPOUND FOR TREATMENT OF BACTERIAL INFECTION
KR20220007688A (ko) * 2019-05-30 2022-01-18 쭈어허 파마수티컬 그룹 코., 엘티디 항균성 아미노글리코사이드 유도체
WO2021121387A1 (zh) * 2019-12-19 2021-06-24 南京明德新药研发有限公司 化合物在制药中的应用
CN113292499B (zh) * 2020-02-24 2024-05-28 齐鲁制药有限公司 一种β-内酰胺酶抑制剂的新制备方法及其中间体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100463403C (zh) 2006-03-20 2009-02-18 腾讯科技(深圳)有限公司 一种基于点对点技术的图片共享***和方法
JP4809097B2 (ja) 2006-03-29 2011-11-02 ルネサスエレクトロニクス株式会社 受信回路及び受信方法
RU2769076C2 (ru) 2011-06-17 2022-03-28 Пфайзер Анти-Инфективз Аб Способ получения гетероциклических соединений, включая транс-7-оксо-6-(сульфокси)-1,6-диазабицикло[3.2.1]октан-2-карбоксамид и его соли
US9505761B2 (en) * 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
KR20150003777A (ko) * 2012-03-30 2015-01-09 큐비스트 파마슈티컬즈 인코포레이티드 이속사졸 β-락타마제 억제제
MX366948B (es) 2012-05-30 2019-07-30 Meiji Seika Pharma Co Ltd Nuevo inhibidor de beta-lactamasa y proceso para prepararlo.
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ

Also Published As

Publication number Publication date
CA3026322A1 (en) 2017-12-07
CN109311881A (zh) 2019-02-05
AU2017274131B2 (en) 2020-10-08
KR102392350B1 (ko) 2022-04-29
MY193239A (en) 2022-09-27
JP2019517501A (ja) 2019-06-24
KR20190015350A (ko) 2019-02-13
ES2863725T3 (es) 2021-10-11
US20200010467A1 (en) 2020-01-09
CA3026322C (en) 2023-08-15
JP6929881B2 (ja) 2021-09-01
RU2741963C2 (ru) 2021-02-01
AU2017274131A1 (en) 2019-01-24
US10738051B2 (en) 2020-08-11
ZA201808552B (en) 2022-11-30
EP3466950B1 (en) 2021-02-24
RU2018146128A3 (ja) 2020-07-10
RU2018146128A (ru) 2020-07-10
EP3466950A4 (en) 2019-11-20
WO2017206947A1 (zh) 2017-12-07
CN109311881B (zh) 2021-07-13
EP3466950A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2018010192A (es) Inhibidores de glucosidasa.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX2018010191A (es) Inhibidores de glucosidasa.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2020006613A (es) Derivados de aril-bipiridina amina como inhibidores de fosfatidilinositol fosfato cinasa.
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX2015017156A (es) Inhibidores de bace.
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
SG11201907945YA (en) Azetidine derivative
MX2019006768A (es) Peptidos antimicrobianos.
MX2021015514A (es) Compuesto heterociclico.
JOP20170164A1 (ar) مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.